First slide

OGT products are created by scientists for scientists. We're proud to participate in ACMG 2021 and introduce CytoSure Constitutional NGS for a painless transition from arrays to NGS in constitutional ID and DD analysis.

Please visit our virtual booth to meet our team and learn more about our products for FISH, microarray and NGS.

CytoCell® – High-quality DNA FISH probes for the detection of genetic aberrations found in cancer and inherited genetic diseases

CytoSure® – Featuring the new constitutional NGS platform for cytogenetic research, alongside a broad range of arrays for rare disease and cancer research

SureSeq™ – Choose from preloaded NGS panels for haematological and solid tumour cancer research, or we can help you create your own.




Registered ACMG attendees are invited to join us for this 30-minute Webinar on demand. Access the presentation from the Product Theater tab on the ACMG virtual meeting platform.  

Clinical utility evaluation of a NGS based assay for the detection of genetic modifiers in families with reduced penetrance or uncertain copy number variants

Presented by:

Elizabeth McCready, PHD, FCCMG, Hamilton Regional Laboratory Medicine Program, Associate Professor, McMaster University

During the presentation Dr. McCready will examine the utility of a next generation sequencing (NGS) panel, CytoSure Constitutional NGS, to identify relevant variants in families with reduced penetrance or uncertain copy number variants (CNVs). Findings from this pilot cohort were compared to data from chromosome microarray analysis to evaluate feasibility of the NGS platform for copy number detection and its utility in identifying single nucleotide variants (SNVs) acting synergistically with CNVs to affect phenotype.

Followed by a LIVE Q&A on Friday, April 16, at 2:30 PM EST with Dr. McCready and Dr. Huiyan Jin, NGS Field Application Scientist, OGT. 

Visit the OGT sponsor page on the ACMG meeting platform for links to these events.

Email questions to